Translating biological insights into improved management of endometrial cancer
Cet article décrit les caractéristiques clinicopathologiques et la classification moléculaire des cancers de l'endomètre, présente un nouveau modèle de stadification puis examine le rôle des nouveaux agents thérapeutiques dans l'évolution des prises en charge de la maladie
Endometrial cancer (EC) is the most common gynaecological cancer among women in high-income countries, with both incidence and mortality continuing to increase. The complexity of the management of patients with EC has evolved with greater comprehension of the underlying biology and heterogeneity of this disease. With a growing number of novel therapeutic agents available, emerging treatment regimens seem to have the potential to help to address the concerning trends in EC-related mortality. In this Review, we describe the epidemiology, histopathology and molecular classification of EC as well as the role of the new (2023) International Federation of Gynecologists and Obstetricians (FIGO) staging model. Furthermore, we provide an overview of disease management in the first-line and recurrent disease settings. With increasing use of molecular profiling and updates in treatment paradigms, we also summarize new developments in this rapidly changing treatment landscape.
Nature Reviews Clinical Oncology , résumé, 2024